Bulletin
Investor Alert

New York Markets Open in:

Market Pulse Archives

Jan. 11, 2022, 9:42 a.m. EST

GlaxoSmithKline, Vir shares up as U.S. orders more doses of COVID treatment sotrovimab

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    GlaxoSmithKline PLC ADR (GSK)
  • X
    GlaxoSmithKline PLC (GSK)
  • X
    Vir Biotechnology Inc. (VIR)

or Cancel Already have a watchlist? Log In

By Barbara Kollmeyer

GlaxoSmithKline /zigman2/quotes/209463850/composite GSK +2.42% /zigman2/quotes/200381158/delayed UK:GSK -0.46% and partner Vir Biotechnology /zigman2/quotes/214486077/composite VIR -1.55% said Tuesday that the U.S. government will buy 600,000 doses of sotrovimab, an investigational monoclonal antibody for early COVID-19 treatment. The extra doses will be delivered in the first quarter of 2022 to the U.S., which has an option to purchase more in the second quarter. The companies now have total binding agreements for 1.7 million doses worldwide. Sotrovimab was granted emergency use authorization by the Food and Drug Administration in May 2021 for treatment of mild to moderate COVID-19 in at-risk adults and children 12 and older. Preclinical data has shown sotrovimab is effective against all COVID-19 variants, including delta and omicron. Shares of Glaxo rose 1% in London and Vir shares climbed 3% in the U.S.

/zigman2/quotes/209463850/composite
US : U.S.: NYSE
$ 44.37
+1.05 +2.42%
Volume: 3.63M
May 16, 2022 4:00p
P/E Ratio
16.09
Dividend Yield
4.51%
Market Cap
$108.55 billion
Rev. per Employee
$552,510
loading...
/zigman2/quotes/200381158/delayed
UK : U.K.: London
1,790.20 p
-8.20 -0.46%
Volume: 1.17M
May 17, 2022 12:13p
P/E Ratio
17.74
Dividend Yield
2.90%
Market Cap
£88.83 billion
Rev. per Employee
£404,857
loading...
/zigman2/quotes/214486077/composite
US : U.S.: Nasdaq
$ 22.28
-0.35 -1.55%
Volume: 770,105
May 16, 2022 4:00p
P/E Ratio
2.46
Dividend Yield
N/A
Market Cap
$3.00 billion
Rev. per Employee
$5.24M
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.